BUSINESS BRIEFING / PHARMACEUTICALS
- Share via
Swiss drug maker Roche officially launched its $42-billion hostile offer for the 44% of Genentech Inc. it doesn’t already own.
As expected, Roche said it would pay $86.50 a share for all remaining publicly held shares of Genentech, the developer of Avastin and other groundbreaking cancer treatments. Roche, which is based in Basil, Switzerland, already holds a 56% stake in Genentech of South San Francisco.
Roche said its new offer was aimed directly at shareholders, bypassing the board. The offer is significantly lower than the $100-per-share value analysts had been touting for several months. Shares of Genentech fell 30 cents to $82.70.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
